Global vaccine race lets biotech companies' value surge

The coronavirus-pandemic is reshaping the biotech industry: Investors are piling in to small, often unproven companies in hopes they can produce a vaccine in the coming months. Those companies in turn, are spending big to expand production facilities for vaccines that aren't yet fully tested, nor certified. It's a gamble for both investor and company and it reflects the urgency for a vaccine as well as the potential to make money.

What's beyond doubt is that thanks to hi-tech methods used by the likes of CureVac, research is moving faster than ever before. It used to take 10 to 15 years to get a vaccine to market.

Now some companies have reached the clinical trial phase in a matter of months.

Trusted institutions are expecting a breakthrough as early as next year.

No other product in the world has a larger potential market. Many nations have already placed orders for hundreds of millions of doses. CureVac plans to produce a billion a year, if its vaccine comes to fruition. The question is whose will hit the market first.

MOCTEN

 

In January 1993, EUNET launched the first online news website, MOCTEN.com (stands for Music Opinions Culture Technology Economy News), led by Eric Bach, Teus Hagen, Peter Collinson, Julf Helsingius, Daniel Karrenberg,...  Read more

×